ASC-J9 suppresses castration-resistant prostate cancer growth through degradation of full-length and splice variant androgen receptors

Shinichi Yamashita, Kuo Pao Lai, Kun Lung Chuang, Defeng Xu, Hiroshi Miyamoto, Tatsuo Tochigi, See Tong Pang, Lei Li, Yoichi Arai, Hsing Jien Kung, Shuyuan Yeh, Chawnshang Chang

Research output: Contribution to journalArticle

91 Citations (Scopus)

Abstract

Early studies suggested androgen receptor (AR) splice variants might contribute to the progression of prostate cancer (PCa) into castration resistance. However, the therapeutic strategy to target these AR splice variants still remains unresolved. Through tissue survey of tumors from the same patients before and after castration resistance, we found that the expression of AR3, a major AR splice variant that lacks the AR ligand-binding domain, was substantially increased after castration resistance development. The currently used antiandrogen, Casodex, showed little growth suppression in CWR22Rv1 cells. Importantly, we found that AR degradation enhancer ASC-J9 could degrade both full-length (fAR) and AR3 in CWR22Rv1 cells as well as in C4-2 and C81 cells with addition of AR3. The consequences of such degradation of both fAR and AR3 might then result in the inhibition of AR transcriptional activity and cell growth in vitro. More importantly, suppression of AR3 specifically by short-hairpin AR3 or degradation of AR3 by ASC-J9 resulted in suppression of AR transcriptional activity and cell growth in CWR22Rv1-fARKD (fAR knockdown) cells in which DHT failed to induce, suggesting the importance of targeting AR3. Finally, we demonstrated the in vivo therapeutic effects of ASC-J9 by showing the inhibition of PCa growth using the xenografted model ofCWR22Rv1 cells orthotopically implanted into castrated nude mice with undetectable serum testosterone. These results suggested that targeting both fAR- and AR3-mediated PCa growth by ASC-J9 may represent the novel therapeutic approach to suppress castration-resistant PCa. Successful clinical trials targeting both fAR and AR3 may help us to battle castration-resistant PCa in the future.

Original languageEnglish
Pages (from-to)74-83
Number of pages10
JournalNeoplasia
Volume14
Issue number1
DOIs
Publication statusPublished - Jan 1 2012
Externally publishedYes

Fingerprint

Castration
Androgen Receptors
Prostatic Neoplasms
Growth
Androgen Antagonists
Therapeutic Uses
Nude Mice
Testosterone
Clinical Trials
Ligands
Therapeutics
Serum
Neoplasms

ASJC Scopus subject areas

  • Cancer Research

Cite this

ASC-J9 suppresses castration-resistant prostate cancer growth through degradation of full-length and splice variant androgen receptors. / Yamashita, Shinichi; Lai, Kuo Pao; Chuang, Kun Lung; Xu, Defeng; Miyamoto, Hiroshi; Tochigi, Tatsuo; Pang, See Tong; Li, Lei; Arai, Yoichi; Kung, Hsing Jien; Yeh, Shuyuan; Chang, Chawnshang.

In: Neoplasia, Vol. 14, No. 1, 01.01.2012, p. 74-83.

Research output: Contribution to journalArticle

Yamashita, S, Lai, KP, Chuang, KL, Xu, D, Miyamoto, H, Tochigi, T, Pang, ST, Li, L, Arai, Y, Kung, HJ, Yeh, S & Chang, C 2012, 'ASC-J9 suppresses castration-resistant prostate cancer growth through degradation of full-length and splice variant androgen receptors', Neoplasia, vol. 14, no. 1, pp. 74-83. https://doi.org/10.1593/neo.111436
Yamashita, Shinichi ; Lai, Kuo Pao ; Chuang, Kun Lung ; Xu, Defeng ; Miyamoto, Hiroshi ; Tochigi, Tatsuo ; Pang, See Tong ; Li, Lei ; Arai, Yoichi ; Kung, Hsing Jien ; Yeh, Shuyuan ; Chang, Chawnshang. / ASC-J9 suppresses castration-resistant prostate cancer growth through degradation of full-length and splice variant androgen receptors. In: Neoplasia. 2012 ; Vol. 14, No. 1. pp. 74-83.
@article{3d64f56a75624815a6bf74e654c13f20,
title = "ASC-J9 suppresses castration-resistant prostate cancer growth through degradation of full-length and splice variant androgen receptors",
abstract = "Early studies suggested androgen receptor (AR) splice variants might contribute to the progression of prostate cancer (PCa) into castration resistance. However, the therapeutic strategy to target these AR splice variants still remains unresolved. Through tissue survey of tumors from the same patients before and after castration resistance, we found that the expression of AR3, a major AR splice variant that lacks the AR ligand-binding domain, was substantially increased after castration resistance development. The currently used antiandrogen, Casodex, showed little growth suppression in CWR22Rv1 cells. Importantly, we found that AR degradation enhancer ASC-J9 could degrade both full-length (fAR) and AR3 in CWR22Rv1 cells as well as in C4-2 and C81 cells with addition of AR3. The consequences of such degradation of both fAR and AR3 might then result in the inhibition of AR transcriptional activity and cell growth in vitro. More importantly, suppression of AR3 specifically by short-hairpin AR3 or degradation of AR3 by ASC-J9 resulted in suppression of AR transcriptional activity and cell growth in CWR22Rv1-fARKD (fAR knockdown) cells in which DHT failed to induce, suggesting the importance of targeting AR3. Finally, we demonstrated the in vivo therapeutic effects of ASC-J9 by showing the inhibition of PCa growth using the xenografted model ofCWR22Rv1 cells orthotopically implanted into castrated nude mice with undetectable serum testosterone. These results suggested that targeting both fAR- and AR3-mediated PCa growth by ASC-J9 may represent the novel therapeutic approach to suppress castration-resistant PCa. Successful clinical trials targeting both fAR and AR3 may help us to battle castration-resistant PCa in the future.",
author = "Shinichi Yamashita and Lai, {Kuo Pao} and Chuang, {Kun Lung} and Defeng Xu and Hiroshi Miyamoto and Tatsuo Tochigi and Pang, {See Tong} and Lei Li and Yoichi Arai and Kung, {Hsing Jien} and Shuyuan Yeh and Chawnshang Chang",
year = "2012",
month = "1",
day = "1",
doi = "10.1593/neo.111436",
language = "English",
volume = "14",
pages = "74--83",
journal = "Neoplasia",
issn = "1522-8002",
publisher = "Elsevier Inc.",
number = "1",

}

TY - JOUR

T1 - ASC-J9 suppresses castration-resistant prostate cancer growth through degradation of full-length and splice variant androgen receptors

AU - Yamashita, Shinichi

AU - Lai, Kuo Pao

AU - Chuang, Kun Lung

AU - Xu, Defeng

AU - Miyamoto, Hiroshi

AU - Tochigi, Tatsuo

AU - Pang, See Tong

AU - Li, Lei

AU - Arai, Yoichi

AU - Kung, Hsing Jien

AU - Yeh, Shuyuan

AU - Chang, Chawnshang

PY - 2012/1/1

Y1 - 2012/1/1

N2 - Early studies suggested androgen receptor (AR) splice variants might contribute to the progression of prostate cancer (PCa) into castration resistance. However, the therapeutic strategy to target these AR splice variants still remains unresolved. Through tissue survey of tumors from the same patients before and after castration resistance, we found that the expression of AR3, a major AR splice variant that lacks the AR ligand-binding domain, was substantially increased after castration resistance development. The currently used antiandrogen, Casodex, showed little growth suppression in CWR22Rv1 cells. Importantly, we found that AR degradation enhancer ASC-J9 could degrade both full-length (fAR) and AR3 in CWR22Rv1 cells as well as in C4-2 and C81 cells with addition of AR3. The consequences of such degradation of both fAR and AR3 might then result in the inhibition of AR transcriptional activity and cell growth in vitro. More importantly, suppression of AR3 specifically by short-hairpin AR3 or degradation of AR3 by ASC-J9 resulted in suppression of AR transcriptional activity and cell growth in CWR22Rv1-fARKD (fAR knockdown) cells in which DHT failed to induce, suggesting the importance of targeting AR3. Finally, we demonstrated the in vivo therapeutic effects of ASC-J9 by showing the inhibition of PCa growth using the xenografted model ofCWR22Rv1 cells orthotopically implanted into castrated nude mice with undetectable serum testosterone. These results suggested that targeting both fAR- and AR3-mediated PCa growth by ASC-J9 may represent the novel therapeutic approach to suppress castration-resistant PCa. Successful clinical trials targeting both fAR and AR3 may help us to battle castration-resistant PCa in the future.

AB - Early studies suggested androgen receptor (AR) splice variants might contribute to the progression of prostate cancer (PCa) into castration resistance. However, the therapeutic strategy to target these AR splice variants still remains unresolved. Through tissue survey of tumors from the same patients before and after castration resistance, we found that the expression of AR3, a major AR splice variant that lacks the AR ligand-binding domain, was substantially increased after castration resistance development. The currently used antiandrogen, Casodex, showed little growth suppression in CWR22Rv1 cells. Importantly, we found that AR degradation enhancer ASC-J9 could degrade both full-length (fAR) and AR3 in CWR22Rv1 cells as well as in C4-2 and C81 cells with addition of AR3. The consequences of such degradation of both fAR and AR3 might then result in the inhibition of AR transcriptional activity and cell growth in vitro. More importantly, suppression of AR3 specifically by short-hairpin AR3 or degradation of AR3 by ASC-J9 resulted in suppression of AR transcriptional activity and cell growth in CWR22Rv1-fARKD (fAR knockdown) cells in which DHT failed to induce, suggesting the importance of targeting AR3. Finally, we demonstrated the in vivo therapeutic effects of ASC-J9 by showing the inhibition of PCa growth using the xenografted model ofCWR22Rv1 cells orthotopically implanted into castrated nude mice with undetectable serum testosterone. These results suggested that targeting both fAR- and AR3-mediated PCa growth by ASC-J9 may represent the novel therapeutic approach to suppress castration-resistant PCa. Successful clinical trials targeting both fAR and AR3 may help us to battle castration-resistant PCa in the future.

UR - http://www.scopus.com/inward/record.url?scp=84863056052&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84863056052&partnerID=8YFLogxK

U2 - 10.1593/neo.111436

DO - 10.1593/neo.111436

M3 - Article

VL - 14

SP - 74

EP - 83

JO - Neoplasia

JF - Neoplasia

SN - 1522-8002

IS - 1

ER -